Cell proliferation and apoptosis in prostate needle biopsies with adenocarcinoma Gleason score 6 or 7

Analytical and Quantitative Cytology and Histology

Volumn 34, Issue 2, 2012, Pages 61-65

  Lopez Beltran, Antonio ^a   Cheng, Liang ^b   Blanca, Ana ^c   Montironi, Rodolfo ^d  

^a Universidad de Cordoba   (Spain)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^d UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Apoptosis; Cell proliferation; Ki 67; Needle biopsy; Prostate cancer

Indexed keywords

MONOCLONAL ANTIBODY KI 67; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER STAGING; CELL PROLIFERATION; CORRELATIONAL STUDY; DISEASE ASSOCIATION; GLEASON SCORE; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATECTOMY; PROTEIN EXPRESSION; SEGMENTAL DYSTONIA;

ADENOCARCINOMA; AGED; APOPTOSIS; BIOPSY, NEEDLE; CELL DIVISION; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM GRADING; PROSTATE; PROSTATIC NEOPLASMS;

EID: 84861007852     PISSN: 08846812     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Epstein JI, Pizov G, Walsh PC: Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993;71:11-16
2. Bostwick DG: Gleason grading of prostatic needle biopsies: Correlation with grade in 316 matched prostatectomies. Am J Surg Pathol 1994;18:796-803
3. Harris DR, Savill J: Apoptosis and the prostate. Br J Urol 1995;75:27-33
4. Montironi R, Pomante R, Diamanti L, Magi-Galluzzi C: Apoptosis in prostate adenocarcinoma following complete androgen ablation. Urol Int (Suppl 1) 1998;60:25-29
5. Edge SB, Byrd DR, Compton CC, Fritz AG, Green FL, Trotti A (editors): AJCC Cancer Staging Handbook. 7th edition. New York, Springer, 2010
6. Aihara M, Truong LD, Dunn JK, Wheeler TM, Scardino PT, Thompson TC: Frequency of apoptotic bodies positively correlates with Gleason grade in prostate cancer. Hum Pathol 1994;25:797-801
7. Gavrieli Y, Sherman Y, Bensasson SA: Identification of programmed cell death in situ via specific labelling of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501
8. Wyllie AH: Apoptosis and the regulation of cell numbers in normal and neoplastic tissues: An overview. Cancer Metast Rev 1992;11:95-103
9. Haussler O, Epstein JI, Amin MB, Heitz PU, Hailemariam S: Cell proliferation, apoptosis, oncogene, and tumor suppressor gene status in adenosis with respect to benign prostatic hyperplasia, prostatic intraepithelial neoplasia, and cancer. Hum Pathol 1999;30:1077-1086
10. Koch M, de Miguel M, Höfler H, Diaz-Cano SJ: Kinetic profiles of intraepithelial and invasive prostatic neoplasia: The key role of down-regulated apoptosis in tumor progression. Virchows Arch 2000;436:413-420
11. Berges RR, Vukanovic J, Epstein JI, CarMichel M, Cisek L, Johnson DE, Veltri RW, Walsh PC, Isaacs JT: Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Can Res 1995;1:473-480
12. Montironi R, Galluzzi CM, Diamanti L, Giannulis I, Pisani E, Scarpelli M: Prostatic intraepithelial neoplasia: Expression and location of proliferating cell nuclear antigen in epithelial, endothelial, and stromal nuclei. Virchows Arch A Pathol Anat 1993;422:185-192
13. Brown C, Sauvageot J, Kahane H, Epstein JI: Cell proliferation and apoptosis in prostate cancer: Correlation with pathologic stage? Mod Pathol 1996;9:205-209
14. Gaffney EF: The extent of apoptosis in different types of high grade prostatic carcinoma. Histopathology 1994;25:269-273
15. Aihara M, Scardino PT, Truong LD, Wheeler TM, Goad JR, Yang G, Thompson TC: The frequency of apoptosis correlates with prognosis of Gleason grade 3 adenocarcinoma of the prostate. Cancer 1995;75;522-529
16. Gonzalez-Campora R, Davalos-Casanova G, Beato-Moreno A, Luque RJ, Alvarez-Kindelan J, Requena MJ, Montironi R, Lopez-Beltrán A: Apoptotic and proliferation indexes in primary superficial bladder tumors. Cancer Lett 2006;242:266-272
17. Lopez-Beltran A, Maclennan GT, de la Haba-Rodriguez J, Montironi R, Cheng L: Research advances in apoptosismediated cancer therapy: A review. Anal Quant Cytol Histol 2007;29:71-78
18. Nagao K, Yamamoto Y, Hara T, Komatsu H, Inoue R, Matsuda K, Matsumoto H, Hara T, Sakano S, Baba Y, Matsuyama H: Ki67 and BUBR1 may discriminate clinically insignificant prostate cancer in the PSA range < 4 ng/ml. Jpn J Clin Oncol 2011;41:555-564
19. Zellweger T, Günther S, Zlobec I, Savic S, Sauter G, Moch H, Mattarelli G, Eichenberger T, Curschellas E, Rüfenacht H, Bachmann A, Gasser TC, Mihatsch MJ, Bubendorf L: Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer. Int J Cancer 2009;124:2116-2123
20. Mazzucchelli R, Barbisan F, Santinelli A, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R: Immunohistochemical expression of prostate stem cell antigen in cystoprostatectomies with incidental prostate cancer. Int J Immunopathol Pharmacol 2009;22:755-762